Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694020 | 0.90 | CACNA1H (0.46) | SMN1; SMN2USP2CYP3A4ALDH1A1CYP2C9 | |
| SCHEMBL12693467 | 0.89 | GAA (0.46) | TBXA2RALDH1A1GAA | |
| SCHEMBL12693472 | 0.88 | GAA (0.50) | TBXA2RALDH1A1NPC1GAA | |
| SCHEMBL13101153 | 0.86 | KMT2A (0.52) | SMN1; SMN2USP2TBXA2RCYP3A4ALDH1A1 | |
| SCHEMBL13112980 | 0.84 | GAA (0.42) | TBXA2RALDH1A1GAA | |
| SCHEMBL693279 | 0.84 | NAMPT (0.46) | SMN1; SMN2TBXA2RALDH1A1NPC1GAA | |
| SCHEMBL13101155 | 0.84 | GAA (0.41) | TBXA2RALDH1A1GAA | |
| SCHEMBL13101154 | 0.83 | MAPT (0.45) | SMN1; SMN2TBXA2RALDH1A1GAAHTT | |
| SCHEMBL693145 | 0.82 | TBXA2R (0.55) | TBXA2RCYP2C9CYP2C19 | |
| SCHEMBL12253135 | 0.82 | CACNA1H (0.42) | SMN1; SMN2USP2TBXA2RCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2421838-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SMN1; SMN2 642/4885USP2 1309/4885TBXA2R 2704/4885 |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SMN1; SMN2 642/4885USP2 1309/4885TBXA2R 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.